PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway.
Hodgins JJ, Abou-Hamad J, O'Dwyer CE, Hagerman A, Yakubovich E, Tanese de Souza C, Marotel M, Buchler A, Fadel S, Park MM, et al. J Exp Med. 2024 Jul 1; 221(7). Epub 2024 Jun 13.